Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Invitae Corp (NY: NVTA )

3.590 -0.100 (-2.71%)
Streaming Delayed Price Updated: 12:00 PM EDT, May 24, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 3,427,559
Open 3.570
Bid (Size) 3.580 (20)
Ask (Size) 3.590 (35)
Prev. Close 3.690
Today's Range 3.420 - 3.620
52wk Range 3.315 - 35.51
Shares Outstanding 217,339,666
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
This Book Changed Warren Buffett's Life
Buffett started buying stocks at 11 and as a teenager was mostly a trader, not an investor. He played the chart. 
Via Talk Markets
Cathie Wood Just Bought More Invitae (NVTA) Stock. Here’s Why.
Despite being down more than 60% year-to-date, Cathie Wood's Ark Invest remains confident in its thesis behind NVTA stock. 
Via InvestorPlace

Performance

YTD
-76.97%
-76.97%
1 Month
-36.80%
-36.80%
3 Month
-60.02%
-60.02%
6 Month
-80.44%
-80.44%
1 Year
-87.29%
-87.29%

More News

Read More
Analyst Ratings for Invitae
Via Benzinga
Recap: Invitae Q1 Earnings
Via Benzinga
FDA Warns Against Relying On Screening Tests For Prenatal Diagnosis
Via Benzinga
Expert Ratings for Invitae
Via Benzinga
Stocks That Hit 52-Week Lows On Wednesday
Via Benzinga
Stocks That Hit 52-Week Lows On Thursday
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Growth Stocks: Sell or Buy More?
Via Talk Markets
Will CPI Report Ruin The Biggest Stock Market Rally In 20 Months?
Via Talk Markets
Invitae Shares Fall As Q4 Earnings Fall Short Of Street Expectation
Via Benzinga
This Week's 5 Must-See Earnings Charts
Via Talk Markets
The Daily Biotech Pulse: Orphazyme Plunges On Regulatory Setback In Europe, Pulmonx Earnings Disappoint, Amicus Declines To Spin Off Genetic Medicine Company
Via Benzinga
Biotech Stocks Are Down And Out; Can These 2022 Trends Save Them?
Via Investor's Business Daily
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
The Week Ahead In Biotech (Feb. 20-26): Reata Awaits FDA Decision, Bausch Health, Moderna Lead Earnings News Flow
Via Benzinga
Rising Cases of Early-Onset Colorectal Cancer Calls for Expanded Biotech Screening Methods
Via FinancialNewsMedia
Stocks That Hit 52-Week Lows On Wednesday
Via Benzinga
63 Biggest Movers From Friday
Via Benzinga
What Especially Stood Out From Invitae's Q3 Results
Via The Motley Fool
3 Stocks to Buy From Catastrophic Price Action
Via InvestorPlace
75 Biggest Movers From Yesterday
Via Benzinga
Why Are Invitae's Shares Plunging Today?
Via Benzinga
58 Stocks Moving In Monday's Mid-Day Session
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.